Product Overview
Composition
Active ingredient:
Antibodies to brain-specific protein S-100 affinity purified - 0.003 g *.
Excipients:
lactose monohydrate 0.267 g,
microcrystalline cellulose 0.03 g,
magnesium stearate 0.003 g
* are applied to lactose monohydrate in the form of a water-alcohol mixture with a content of not more than 10 -16 ng / g of the active form of the active substance.
Antibodies to brain-specific protein S-100 affinity purified - 0.003 g *.
Excipients:
lactose monohydrate 0.267 g,
microcrystalline cellulose 0.03 g,
magnesium stearate 0.003 g
* are applied to lactose monohydrate in the form of a water-alcohol mixture with a content of not more than 10 -16 ng / g of the active form of the active substance.
pharmachologic effect
The drug has a calming, anti-anxiety (anxiolytic) effect, without causing unwanted hypnogenic and muscle relaxant effects. Improves the tolerance of psycho-emotional stress. It has a stress-protective, nootropic, antiamnestic, antihypoxic, neuroprotective, antiasthenic, antidepressant effect.
In conditions of intoxication, hypoxia, in conditions after acute cerebrovascular accident, it has a neuroprotective effect, limits the damage zone, normalizes the learning and memory processes in the central nervous system (CNS).
It inhibits lipid peroxidation.
Modifies the functional activity of the S-100 protein, which carries out the conjugation of synaptic (informational) and metabolic processes in the brain. By providing a GABA-mimetic and neurotrophic effect, it increases the activity of stress-limiting systems and helps to restore the processes of neuronal plasticity.
In conditions of intoxication, hypoxia, in conditions after acute cerebrovascular accident, it has a neuroprotective effect, limits the damage zone, normalizes the learning and memory processes in the central nervous system (CNS).
It inhibits lipid peroxidation.
Modifies the functional activity of the S-100 protein, which carries out the conjugation of synaptic (informational) and metabolic processes in the brain. By providing a GABA-mimetic and neurotrophic effect, it increases the activity of stress-limiting systems and helps to restore the processes of neuronal plasticity.
Indications
Tenoten is indicated for use in adults.
Anxiety conditions in neurotic and neurosis-like conditions, psychosomatic diseases; stress disorders with increased nervous tension, irritability, anxiety and autonomic reactions, as part of complex therapy.
Anxiety in neurological disorders of a discirculatory origin, accompanied by instability of the emotional background, irritability, memory loss, autonomic disorders, as part of complex therapy.
Anxiety conditions in neurotic and neurosis-like conditions, psychosomatic diseases; stress disorders with increased nervous tension, irritability, anxiety and autonomic reactions, as part of complex therapy.
Anxiety in neurological disorders of a discirculatory origin, accompanied by instability of the emotional background, irritability, memory loss, autonomic disorders, as part of complex therapy.
Pregnancy and lactation
The safety of Tenoten in pregnant women and during lactation has not been studied. If necessary, take the drug should take into account the ratio of "benefit-risk".
Contraindications
Increased individual sensitivity to the components of the drug, children's age up to 18 years.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Side effects
Possible reactions of increased individual sensitivity to the components of the drug.
Interaction
Cases of incompatibility with other drugs have not yet been reported.
How to take, course of administration and dosage
The risk is not intended to divide the tablet into parts.
Inside. At one time - 1 or 2 tablets (keep in mouth until completely dissolved - not during meals).
Take 2 times a day; if necessary - up to 4 receptions per day. The course of treatment is 1-3 months; if necessary, the course of treatment can be extended up to 6 months or repeated after 1-2 months.
In the absence of persistent improvement within 3-4 weeks after the start of treatment, you must consult a doctor.
Inside. At one time - 1 or 2 tablets (keep in mouth until completely dissolved - not during meals).
Take 2 times a day; if necessary - up to 4 receptions per day. The course of treatment is 1-3 months; if necessary, the course of treatment can be extended up to 6 months or repeated after 1-2 months.
In the absence of persistent improvement within 3-4 weeks after the start of treatment, you must consult a doctor.
Overdose
In case of accidental overdose, dyspeptic symptoms are possible due to excipients that are part of the drug.
Description
The tablets are flat-cylindrical, with a risk and a chamfer from white to almost white.
MATERIA MEDICA is inscribed on the flat side with the risk, TENOTEN is inscribed on the other flat side.
Special instructions
The composition of the drug includes lactose, and therefore it is not recommended for patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or congenital lactase deficiency.
Due to the presence of activating properties in the action of Tenoten, the last dose should be taken no later than 2 hours before bedtime. Influence on the ability to drive vehicles The negative effect of Tenoten on the ability to drive vehicles and other potentially dangerous mechanisms has not been identified.
Due to the presence of activating properties in the action of Tenoten, the last dose should be taken no later than 2 hours before bedtime. Influence on the ability to drive vehicles The negative effect of Tenoten on the ability to drive vehicles and other potentially dangerous mechanisms has not been identified.
Release form
Lozenges.
On 20 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. 1 or 2 blister packs together with instructions for medical use are placed in a pack of cardboard.
On 20 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. 1 or 2 blister packs together with instructions for medical use are placed in a pack of cardboard.
Storage conditions
At a temperature of no higher than 25 ° C.
Keep out of the reach of children.
During the period of use of the drug, store blister packs in a cardboard box provided by the manufacturer.
Keep out of the reach of children.
During the period of use of the drug, store blister packs in a cardboard box provided by the manufacturer.
Shelf life
3 years. Do not use after the expiration date.
